Key result
Equivalent weight loss through a 4-month hypocaloric diet produced comparable reductions in muscle sympathetic nerve activity and whole-body norepinephrine spillover in obese subjects regardless of baseline glucose tolerance.
Why the study?
Does baseline metabolic status influence the degree of sympathoinhibition attained following equivalent dietary weight loss in obese subjects?
Cohort (n=54)
No
Does baseline metabolic status influence the degree of sympathoinhibition attained following equivalent dietary weight loss in obese subjects?
Equivalent weight loss through a hypocaloric diet yields similar reductions in sympathetic nervous system activity in obese subjects regardless of baseline glucose tolerance, driven primarily by improvements in hyperinsulinemia and hyperlipidemia.
Answers are grounded in this paper and cite their sources.
Baseline metabolic status may modulate sympathoinhibition after weight loss; leaves open personalized strategies pending prospective trials.
Background and Purpose: Elevated sympathetic nervous system (SNS) activity is a characteristic of obesity and type 2 diabetes (T2D) that contributes to target organ damage and cardiovascular risk. In this study we examined whether baseline metabolic status influences the degree of sympathoinhibition attained following equivalent dietary weight loss. Methods: Un-medicated obese individuals categorized as normal glucose tolerant (NGT, n=15), impaired glucose tolerant (IGT, n=24) and newly-diagnosed T2D (n=15) consumed a hypocaloric diet (29% fat, 23% protein, 45% carbohydrate) for 4-months. The three groups were matched for baseline age (56 + 1 years), body mass index (BMI, 32.9 + 0.7 kg/m2) and gender. Clinical measurements included whole-body norepinephrine kinetics, muscle sympathetic nerve activity (MSNA, by microneurography), spontaneous cardiac baroreflex sensitivity (BRS) and oral glucose tolerance test. Results: Weight loss averaged -7.5 + 0.8, -8.1 + 0.5 and -8.0 + 0.9 % of body weight in NGT, IGT and T2D groups, respectively. T2D subjects had significantly greater reductions in fasting glucose, 2-h glucose and glucose area under the curve (AUC0-120) compared to NGT and IGT (group effect, P<0.001). Insulinogenic index decreased in IGT and NGT groups and increased in T2D (group x time, P=0.04). The magnitude of reduction in MSNA (-7 + 3, -8 + 4, -15 + 4 burst/100hb, respectively) and whole-body norepinephrine spillover rate (-28 + 8, -18 + 6 and -25 + 7 %, respectively), time effect both P<0.001, did not differ between groups. After adjustment for age and change in body weight, ∆ insulin AUC0-120 was independently associated with reduction in arterial norepinephrine concentration, whilst ∆ LDL-cholesterol and improvement in BRS were independently associated with decrease in MSNA. Conclusions: Equivalent weight loss through hypocaloric diet is accompanied by similar sympathoinhibition in matched obese subjects with different baseline glucose tolerance. Attenuation of hyperinsulinemia and hyperlipidemia, rather than glycemic indices, is associated with reduction in SNS activity following weight loss intervention.
No takes yet. Share an insight, caveat, or question.
Straznicky et al. (2016) conducted a cohort in Obesity with Normal Glucose Tolerance, Impaired Glucose Tolerance, or Type 2 Diabetes (n=54). Hypocaloric diet vs. Baseline (before-after comparison across 3 glucose tolerance groups) was evaluated on Change in muscle sympathetic nerve activity (MSNA) and whole-body norepinephrine spillover rate (p=<0.001). Equivalent weight loss through a 4-month hypocaloric diet produced comparable reductions in muscle sympathetic nerve activity and whole-body norepinephrine spillover in obese subjects regardless of baseline glucose tolerance.
Synapse has enriched 10 related papers. Consider them for comparative context: